Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1

Conditions

Glioma 2Brain Neoplasms 2Prostatic Neoplasms 1Oligodendroglioma 1Neoplasms 1Gliosarcoma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 47Bevacizumab 41Radiotherapy 17Magnetic Resonance Spectroscopy 14Irinotecan 11Nivolumab 8Everolimus 7Radiation 6poly ICLC 5X-Rays 5Phantoms, Imaging 5Carboplatin 5pembrolizumab 4fluorodopa F 18 4Specimen Handling 4Nuclear Medicine Department, Hospital 4Granulocyte-Macrophage Colony-Stimulating Factor 4Erlotinib Hydrochloride 4Carmustine 4ribociclib 3palbociclib 3ivosidenib 3antineoplaston A10 3Vorinostat 3Radiotherapy, Intensity-Modulated 3Radiosurgery 3Modafinil 3Lomustine 3Biopsy 3veliparib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Glioma × octadecyl-(N,N-dimethylpiperidino-4-yl)-phosphate × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00590954 2020-10-19

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
32 enrolled 8 charts
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡